Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance

Documenti analoghi

• Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy
  di: Shi, Jinpeng, et al.
  Pubblicazione: (2017)
• Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
  di: Liu, Sangtian, et al.
  Pubblicazione: (2021)
• Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
  di: Jia, Yijun, et al.
  Pubblicazione: (2020)
• Histone deacetylation, as opposed to promoter methylation, results in epigenetic BIM silencing and resistance to EGFR TKI in NSCLC
  di: Zhao, Mingchuan, et al.
  Pubblicazione: (2018)
• Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
  di: Pan, Yong-hong, et al.
  Pubblicazione: (2018)